Lyra Therapeutics, Inc. Share Price & Technical Analysis
LYRA · $0.70 (0.00%)
Healthcare / Biotechnology
$0.70
0.00%
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflam…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-12% return in Jun, -9% avg return in past 3 year Jun month.
-112% return in 2026, -87% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -42% | -47% | -50% | 40% | 0% | -12% | – | – | – | – | – | – | -112% |
| 25 | -13% | 19% | -41% | -9% | -16% | -69% | -25% | 6% | -8% | -9% | -43% | -18% | -227% |
| 24 | -12% | 15% | 17% | -18% | -93% | -14% | 20% | 2% | -20% | 7% | -24% | 1% | -120% |
| 23 | -10% | -15% | -16% | 17% | 5% | 56% | -20% | 9% | 13% | -24% | 11% | 60% | 86% |
| 22 | -7% | 19% | -18% | 35% | -6% | 3% | 16% | -11% | -12% | -8% | -27% | -11% | -28% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.15M
P/E ratio
—
52W high
$27.42
52W low
$0.31
Volume
2,000
Beta
0.69
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Lyra Therapeutics, Inc. share price today?
- Lyra Therapeutics, Inc. (LYRA) last traded around $0.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LYRA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LYRA. Download the app for real-time alerts.
- How can I analyze Lyra Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.